Cargando…
Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
De novo lipogenesis (DNL) plays an important role in the pathogenesis of hepatic steatosis and also appears to be implicated in hepatic inflammation and fibrosis. Accordingly, the inhibition of acetyl-CoA carboxylase, which catalyzes the rate-limiting step of DNL, might represent a useful approach i...
Autores principales: | Neokosmidis, Georgios, Cholongitas, Evangelos, Tziomalos, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554398/ https://www.ncbi.nlm.nih.gov/pubmed/34754150 http://dx.doi.org/10.3748/wjg.v27.i39.6522 |
Ejemplares similares
-
Acetyl-CoA Carboxylases and Diseases
por: Wang, Yu, et al.
Publicado: (2022) -
WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice
por: Gao, Ying-sheng, et al.
Publicado: (2019) -
Chemical Genetics of Acetyl-CoA Carboxylases
por: Zu, Xuyu, et al.
Publicado: (2013) -
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021) -
The dynamic organization of fungal acetyl-CoA carboxylase
por: Hunkeler, Moritz, et al.
Publicado: (2016)